Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Issue 12 (2nd December 2018)

• Record Type: Journal Article
• Authors: Calzada, Oscar; Switchenko, Jeffrey M.; Maly, Joseph J.; Blum, Kristie A.; Grover, Natalie; Mathews, Stephanie; Park, Steven I.; Gordon, Max; Danilov, Alexey; Epperla, Narendranath; Fenske, Timothy S.; Hamadani, Mehdi; Flowers, Christopher R.; Cohen, Jonathon B.
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 12(2018)
• Page Start: 2862
• Page End: 2870
• Publication Date: 2018-12-02
• Subjects: Mantle cell lymphoma -- deferred therapy -- non-Hodgkin's lymphoma; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1455973
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p = .001), have no B symptoms (83 versus 65% p = .003) and have normal LDH levels at diagnosis (87 versus 55% p < .001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p = .407).